All News
Survival and Mortality in RA: time to move away from “one-size fits all”?
Patients with RA are known to have a higher mortality risk than the general population.
Read Article
Ab0344 #ACR22
CKD2+ a/w incr HCQ levels by 149 ng/mL vs CKD1
400 mg/d dose: incr HCQ levels by 448 ng/mL vs 200
Incr body wt by 15 kg -> decr HCQ levels by 82 ng/mL
Social determinants didn't effect data
>750ng/mL and >1000 predicted of 75% decr flare risk
@Rheumnow #ACRBest https://t.co/p21rqnO4ym
Eric Dein ericdeinmd ( View Tweet)
Abstr 0373 created a scoring system to predict outcomes in SpA pts w/ uveitis
- Poor outcomes seen among smoking hx, females, +HLAB27, axial & peripheral involvement, high disease activity, inflammation, and b/l eye involvement
https://t.co/mGAn0Eel1O
@RheumNow #ACR22 https://t.co/qtJsavtG9z
Akhil Sood MD AkhilSoodMD ( View Tweet)
New 2022 EULAR Recommendations for the Management of RA
The updated '22 EULAR recommendations for the mgmt of RA were initially presented at EULAR '22, and are now in press delineating the most recent developments and perspectives in RA treatment.
https://t.co/xnpOUnpgvy https://t.co/OWcRq7nZ57
Links:
Dr. John Cush RheumNow ( View Tweet)
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Mike Putman EBRheum ( View Tweet)
A group of older patients w/ multimorbidity (5+) drives higher mortality risk in RA.
Crowson et al. stratification 4 clusters. Each cluster = different outcome, younger cluster w/ few comorbidities = no > mortality
https://t.co/IYccicjcyy
Abstr #0246 #ACR22 @Rheumnow #ACRBest https://t.co/ee9sgG3g0l
Aurelie Najm AurelieRheumo ( View Tweet)
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Year in review #ACR22
IV Tocilizumab FDA approved in GCA!!
Randomized trial of iv tocilizumab in PMR - 101 pts. Steroid taper was quicker.
https://t.co/BQT2H8LEFk
@rheumnow https://t.co/4KAYrz1IES
Bella Mehta bella_mehta ( View Tweet)
Very helpful slide on the different MOAs of JAK inhibitors (by Lui C et al.) shared by Dr. Langford
#ACR22 @RheumNow #RheumTwitter #yearinreview https://t.co/9VIOmzNoMq
sheila RHEUMarampa ( View Tweet)
VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a
Max Konig MaxKonigMD ( View Tweet)
Yr in review #ACR22 @RheumNow
🌟GLORIA 2 yr data:
👉Pred 5mg OD vs PBO >65y/o RA
✅⬇️ disease activity (DAS28 -0.38)
✅⬇️ joint damage (sharp/van der heijde -1.7)
❌ 24% ⬆️ a/e
“Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”
Patricia Harkins DrTrishHarkins ( View Tweet)
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Robert B Chao, MD doctorRBC ( View Tweet)
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Julian Segan JulianSegan ( View Tweet)
Year in Review
#ACR22
Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies
@RheumNow https://t.co/EPtOrjJqLd
Eric Dein ericdeinmd ( View Tweet)
Preview of what is sure to be discussed more in detail later..
MIRROR trial of MTX co-administration with pegloticase in treatment of gout.
MTX co-administration improved control of gout, reduced infusion reactions
@RheumNow #ACR22 https://t.co/r0MEq1rkgO
Robert B Chao, MD doctorRBC ( View Tweet)
ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
#ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. C Langford on #YearinReview: ORAL Surveillance noted NNH=16 in pts w/ASCVD compared to NNH 223 in pts w/o ASCVD. This led to FDA warning on all JAKi; how does not this apply to the new JAKi's? Discussion needed with patients when starting this class of drug #ACR22 @rheumnow https://t.co/XtJVap6yjh
TheDaoIndex KDAO2011 ( View Tweet)
Year in review #ACR22
IVIG received FDA approval for dermatomyositis in 2022!
@RheumNow
Bella Mehta bella_mehta ( View Tweet)
Year in Review #ACR22
IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo
First approved Rx for inflammatory myositis
@RheumNow https://t.co/T6qVTQQdTp
Eric Dein ericdeinmd ( View Tweet)
Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDiBdJZn) a few eps back
I disagree w/Dr. Langford re:role in therapy. I use IVIG first line for most all pts w/myositis, grateful for the FDA approval!
#ACR22 @RheumNow https://t.co/BfHZm4Kl49
Mike Putman EBRheum ( View Tweet)